

Genenta Science (NASDAQ: GNTA) is a clinical-stage biotech company pioneering the development of lentivirus-based gene and cell therapy candidates in cancer. Genenta's proprietary gene-based cytokine delivery system is designed to activate the immune system within the tumor and to provide a controlled, targeted and enduring anti-tumor response.


Genenta is:

- pioneering the development of lentiviral **gene & cell therapies**;
 - developing a **proprietary method** of delivering gene modified cell therapies to the tumor by using **TEMs** as a **Trojan horse**;
 - aiming at modifying the tumor microenvironment to **activate** the **immune system** against cancerous tumors;
 - developing a potentially **tumor agnostic** (not restricted to a tumor type nor to a specific tumor antigen) lead product candidate called Temferon.
-
- Addressing an **unmet medical need** in oncology;
 - initially focusing on **GBM** (Glioblastoma Multiforme), the tumor that killed: Edward Kennedy; John McCain; Beau Biden, etc...;
 - based on the agnostic potential of Temferon,

developing a **pipeline** of other solid tumor indications that could potentially respond to treatment;

- in the **clinic** today treating newly diagnosed GBM patients who have an unmethylated MGMT promoter (uMGMT-GBM);
 - generating **encouraging preliminary** data using its Temferon cell therapy product candidate in patients suffering from brain cancer:
 - » Temferon has persisted in some clinical trial patients up to 18 months from treatment,
 - » Temferon reaches the tumor directly,
 - » Temferon has been well tolerated by patients.
 - anticipating preliminary data read-outs in **2022**;
 - planning a Ph. 2 clinical trial application in GBM in Europe in the fourth quarter of **2022**.
-
- A spin-off from **San Raffaele Hospital (OSR)**, a leading center for *ex-vivo* gene therapy;
 - benefiting from strong research output from the founders' laboratories including non-clinical data on **combination therapy** using Temferon and other immuno-oncology treatments;
 - licensing **strong intellectual property** from OSR;
 - experienced with a strong and well-rounded **leadership team**;
 - endowed with a world-class **Board of Directors** and **Advisors**.


NATURAL HOMING OF TEMs TO TUMOR MICROENVIRONMENT



GENENTA SCIENCE S.P.A. (FORMERLY GENENTA SCIENCE S.R.L.)

| FOUNDED | HQ | FOUNDER | CEO | CFO | CMO & HEAD of DEVELOPMENT |
|---------|--------------|---|--------------------|-------------------------|---------------------------|
| 2014 | Milan, Italy | Ospedale Raffaele, Hospital (OSR) Pierluigi Paracchi, Luigi Naldini and Bernhard Gentner | Pierluigi Paracchi | Richard B. Slansky, MBA | Carlo Russo, MD |

FINANCING



All Quota converted to ordinary shares in May 2021, no par value
Ownership*: Insiders= 30%; Institutions= 34%

* Company's approximation upon closing of the IPO and does not reflect the subsequent exercise of the underwriters' over-allotment options.

INTELLECTUAL PROPERTY (IP)

Exclusive options on IP generated from San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), a world leading cell and gene therapy research institution that is a joint venture between OSR and Telethon.

BOARD OF DIRECTORS

STEPHEN
SQUINTO

ROGER
ABRAVANEL

DANIELA
BELLOMO

GUIDO
GUIDI

LUCA
GUIDOTTI

ANTHONY
MARUCCI

PIERLUIGI
PARACCHI

CONTACT INFORMATION

Pierluigi Paracchi, CEO
pierluigi.paracchi@genenta.com
mobile: +39 335 7351868

Richard B. Slansky, CFO
richard.slansky@genenta.com
mobile +1.858.220.0846